- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126732
Ganglion Cell Thickness in Enuresis Nocturna
November 16, 2021 updated by: Yasar Issi, Izmir Bakircay University
Is Ganglion Cell Thickness the Main Problem in Enuresis Nocturna?
The precise role of the intrinsic circadian regulatory mechanism behind the pathogenesis of enuresis is not fully understood, but in theory, circadian rhythm irregularity may be the primary pathogenic mechanism not only for urinary outflow mechanisms but also for nocturnal bladder function.
The proximity between SCN centers that control AVP release, sleep/arousal, voiding, and baroreregulation may provide the basis for circadian rhythm disturbance in one or more of these biological functions.
Ganglion cells containing melanopsin pigment in the retina transmit the information they receive from the outside world about the light-dark state to the SCN via the retinohypothalamic pathway.
Peripapillary retinal nerve fiber layer (RNFL) thickness, optic nerve head and macula are examined most frequently for the diagnosis of glaucoma and the detection of progression with optical coherence tomography (OCT).
If differences in ganglion cell thickness can be detected using OCT in these children, a new avenue in Enuresis Nocturna may be opened.
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Anticipated)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yasar ISSI
- Phone Number: 00905321704131
- Email: yasarissi@yahoo.com
Study Locations
-
-
-
Izmir, Turkey
- Recruiting
- Bakircay University
-
Contact:
- Yasar ISSI
- Phone Number: 00905321704131
- Email: yasarissi@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Pediatric patients aged 5-18 years, with enuresis, without any eye disease
Description
Inclusion Criteria:
- be between the ages of 5-18
- have enuresis
Exclusion Criteria:
- have any eye conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in ganglion cell thickness in enuretic children
Time Frame: Baseline
|
Normal values in RNFL measurements on OCT 75 (lowest)-107.2
(highest)
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 1, 2022
Primary Completion (ANTICIPATED)
April 1, 2022
Study Completion (ANTICIPATED)
July 1, 2022
Study Registration Dates
First Submitted
October 28, 2021
First Submitted That Met QC Criteria
November 16, 2021
First Posted (ACTUAL)
November 19, 2021
Study Record Updates
Last Update Posted (ACTUAL)
November 19, 2021
Last Update Submitted That Met QC Criteria
November 16, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Neoplasms
- Urologic Diseases
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Cysts
- Connective Tissue Diseases
- Urination Disorders
- Mucinoses
- Elimination Disorders
- Urinary Incontinence
- Enuresis
- Ganglion Cysts
- Synovial Cyst
- Nocturnal Enuresis
- Chronobiology Disorders
Other Study ID Numbers
- 341/321
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Circadian Rhythm Disorders
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingSleep | Sleep Disturbance | Anesthesia | Sleep Disorders, Circadian Rhythm | Circadian Rhythm Sleep Disorder | Circadian Rhythm Disorder Caused by Drug | Circadian Rhythm Sleep Disorder, Jet Lag Type | Jet LagNetherlands
-
Brigham and Women's HospitalNSBRICompletedCircadian RhythmUnited States
-
Vanda PharmaceuticalsCompletedCircadian Rhythm Sleep DisordersUnited States
-
Brigham and Women's HospitalNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Taipei Veterans General Hospital, TaiwanNational Yang Ming UniversityRecruitingShift Work Type Circadian Rhythm Sleep DisorderTaiwan
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
Columbia UniversityRecruitingEating Behavior | Shift Work Type Circadian Rhythm Sleep DisorderUnited States
-
Federal University of UberlandiaCompletedShift Work Type Circadian Rhythm Sleep DisorderBrazil
-
University of Alabama at BirminghamAmerican Heart AssociationCompletedBlood Pressure | Circadian RhythmUnited States
-
Samsung Medical CenterCompletedCircadian Rhythm Phase Shift